SQN 400

Drug Profile

SQN 400

Alternative Names: Bacteriochlorin

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scotia Holdings
  • Developer biolitec; QuantaNova
  • Class
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 22 Jan 2002 QuantaNova has the photodynamic therapy assets of Scotia Holdings
  • 03 May 2000 Scotia has signed an agreement with Techniclone Corporation giving Scotia exclusive rights to the latter's vascular targeting agents
  • 20 Oct 1999 Phase-I clinical trials for Liver cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top